188 related articles for article (PubMed ID: 37016578)
1. Red blood cell extracellular vesicles deliver therapeutic siRNAs to skeletal muscles for treatment of cancer cachexia.
Peng B; Yang Y; Wu Z; Tan R; Pham TT; Yeo EYM; Pirisinu M; Jayasinghe MK; Pham TC; Liang K; Shyh-Chang N; Le MTN
Mol Ther; 2023 May; 31(5):1418-1436. PubMed ID: 37016578
[TBL] [Abstract][Full Text] [Related]
2. Combination therapy with anamorelin and a myostatin inhibitor is advantageous for cancer cachexia in a mouse model.
Hanada K; Fukasawa K; Hinata H; Imai S; Takayama K; Hirai H; Ohfusa R; Hayashi Y; Itoh F
Cancer Sci; 2022 Oct; 113(10):3547-3557. PubMed ID: 35849084
[TBL] [Abstract][Full Text] [Related]
3. Genetic deletion of myostatin from the heart prevents skeletal muscle atrophy in heart failure.
Heineke J; Auger-Messier M; Xu J; Sargent M; York A; Welle S; Molkentin JD
Circulation; 2010 Jan; 121(3):419-25. PubMed ID: 20065166
[TBL] [Abstract][Full Text] [Related]
4. Acute inhibition of myostatin-family proteins preserves skeletal muscle in mouse models of cancer cachexia.
Benny Klimek ME; Aydogdu T; Link MJ; Pons M; Koniaris LG; Zimmers TA
Biochem Biophys Res Commun; 2010 Jan; 391(3):1548-54. PubMed ID: 20036643
[TBL] [Abstract][Full Text] [Related]
5. Antibody-directed myostatin inhibition enhances muscle mass and function in tumor-bearing mice.
Murphy KT; Chee A; Gleeson BG; Naim T; Swiderski K; Koopman R; Lynch GS
Am J Physiol Regul Integr Comp Physiol; 2011 Sep; 301(3):R716-26. PubMed ID: 21677277
[TBL] [Abstract][Full Text] [Related]
6. Peptide-2 from mouse myostatin precursor protein alleviates muscle wasting in cancer-associated cachexia.
Ojima C; Noguchi Y; Miyamoto T; Saito Y; Orihashi H; Yoshimatsu Y; Watabe T; Takayama K; Hayashi Y; Itoh F
Cancer Sci; 2020 Aug; 111(8):2954-2964. PubMed ID: 32519375
[TBL] [Abstract][Full Text] [Related]
7. [Role of Activin A and Myostatin in cancer cachexia].
Thissen JP; Loumaye A
Ann Endocrinol (Paris); 2013 May; 74(2):79-81. PubMed ID: 23566617
[TBL] [Abstract][Full Text] [Related]
8. Molecular mechanisms of cancer cachexia-related loss of skeletal muscle mass: data analysis from preclinical and clinical studies.
Martin A; Gallot YS; Freyssenet D
J Cachexia Sarcopenia Muscle; 2023 Jun; 14(3):1150-1167. PubMed ID: 36864755
[TBL] [Abstract][Full Text] [Related]
9. IMB0901 inhibits muscle atrophy induced by cancer cachexia through MSTN signaling pathway.
Liu D; Qiao X; Ge Z; Shang Y; Li Y; Wang W; Chen M; Si S; Chen SZ
Skelet Muscle; 2019 Mar; 9(1):8. PubMed ID: 30922397
[TBL] [Abstract][Full Text] [Related]
10. Myostatin is a novel tumoral factor that induces cancer cachexia.
Lokireddy S; Wijesoma IW; Bonala S; Wei M; Sze SK; McFarlane C; Kambadur R; Sharma M
Biochem J; 2012 Aug; 446(1):23-36. PubMed ID: 22621320
[TBL] [Abstract][Full Text] [Related]
11. Chronic Alcohol Consumption Enhances Skeletal Muscle Wasting in Mice Bearing Cachectic Cancers: The Role of TNFα/Myostatin Axis.
Li Y; Zhang F; Modrak S; Little A; Zhang H
Alcohol Clin Exp Res; 2020 Jan; 44(1):66-77. PubMed ID: 31657476
[TBL] [Abstract][Full Text] [Related]
12. The role of TGF-β signaling in muscle atrophy, sarcopenia and cancer cachexia.
Lan XQ; Deng CJ; Wang QQ; Zhao LM; Jiao BW; Xiang Y
Gen Comp Endocrinol; 2024 Jul; 353():114513. PubMed ID: 38604437
[TBL] [Abstract][Full Text] [Related]
13. Excessive fatty acid oxidation induces muscle atrophy in cancer cachexia.
Fukawa T; Yan-Jiang BC; Min-Wen JC; Jun-Hao ET; Huang D; Qian CN; Ong P; Li Z; Chen S; Mak SY; Lim WJ; Kanayama HO; Mohan RE; Wang RR; Lai JH; Chua C; Ong HS; Tan KK; Ho YS; Tan IB; Teh BT; Shyh-Chang N
Nat Med; 2016 Jun; 22(6):666-71. PubMed ID: 27135739
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of myostatin gene expression in skeletal muscle of fish by in vivo electrically mediated dsRNA and shRNAi delivery.
Terova G; Rimoldi S; Bernardini G; Saroglia M
Mol Biotechnol; 2013 Jun; 54(2):673-84. PubMed ID: 23065364
[TBL] [Abstract][Full Text] [Related]
15. Deliberation on debilitating condition of cancer cachexia: Skeletal muscle wasting.
Dave S; Patel BM
Fundam Clin Pharmacol; 2023 Dec; 37(6):1079-1091. PubMed ID: 37474262
[TBL] [Abstract][Full Text] [Related]
16. Effect of RNA oligonucleotide targeting Foxo-1 on muscle growth in normal and cancer cachexia mice.
Liu CM; Yang Z; Liu CW; Wang R; Tien P; Dale R; Sun LQ
Cancer Gene Ther; 2007 Dec; 14(12):945-52. PubMed ID: 17885675
[TBL] [Abstract][Full Text] [Related]
17. Molecular Pathways: Cachexia Signaling-A Targeted Approach to Cancer Treatment.
Miyamoto Y; Hanna DL; Zhang W; Baba H; Lenz HJ
Clin Cancer Res; 2016 Aug; 22(16):3999-4004. PubMed ID: 27340276
[TBL] [Abstract][Full Text] [Related]
18. Magnolol inhibits myotube atrophy induced by cancer cachexia through myostatin signaling pathway in vitro.
Ge Z; Liu D; Shang Y; Li Y; Chen SZ
J Nat Med; 2020 Sep; 74(4):741-749. PubMed ID: 32601830
[TBL] [Abstract][Full Text] [Related]
19. Valproic acid attenuates skeletal muscle wasting by inhibiting C/EBPβ-regulated atrogin1 expression in cancer cachexia.
Sun R; Zhang S; Hu W; Lu X; Lou N; Yang Z; Chen S; Zhang X; Yang H
Am J Physiol Cell Physiol; 2016 Jul; 311(1):C101-15. PubMed ID: 27122162
[TBL] [Abstract][Full Text] [Related]
20. [Systemic and local mechanisms leading to cachexia in cancer].
Grabiec K; Burchert M; Milewska M; Błaszczyk M; Grzelkowska-Kowalczyk K
Postepy Hig Med Dosw (Online); 2013 Dec; 67():1397-409. PubMed ID: 24493689
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
